BioStock: Aptahem takes the next step in the treatment of sepsis

Sepsis affects millions of people globally every year and results in significant morbidity and mortality. The standard treatment consists mainly of antibiotics, which is not optimal given the risk of antibiotic resistance. A company whose goal is to develop the next generation of emergency drugs against the indication, is Swedish Aptahem with their drug candidate Apta-1.

Read the article at biostock.se:

https://www.biostock.se/en/2023/06/aptahem-takes-the-next-step-in-the-treatment-of-sepsis/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/